Exelixis traded at $20.27 this Tuesday May 17th, increasing $0.01 or 0.05 percent since the previous trading session. Looking back, over the last four weeks, Exelixis gained 11.29 percent. Over the last 12 months, its price fell by 16.72 percent. Looking ahead, we forecast Exelixis to be priced at 19.52 by the end of this quarter and at 18.16 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,707.00 28.00 0.76% -1.88%
Eisai 5,607.00 60.00 1.08% -18.82%
Acadia Pharmaceuticals 16.91 0.31 1.84% -20.37%
Agios Pharmaceuticals 22.30 0.16 0.72% -59.98%
Akebia Therapeutics 0.38 0.002 0.53% -88.80%
Amgen 245.21 1.34 0.55% -2.25%
AstraZeneca 10,424.00 -64.00 -0.61% 31.05%
Bayer 64.27 0.15 0.23% 15.45%
Bluebird Bio 3.59 0.20 5.75% -88.31%
BioMarin Pharmaceutical 77.90 0.58 0.75% 0.72%
Bristol-Myers Squibb 78.18 1.27 1.64% 19.17%
Cytokinetics 42.49 -0.91 -2.10% 77.34%
Esperion Therapeutics 5.94 0.05 0.85% -71.54%
Exelixis 20.27 0.01 0.05% -16.72%
Genmab 2,160.00 60.00 2.86% -6.90%
Glaxosmithkline 44.59 0.22 0.50% 12.63%
Immunogen 3.91 0.09 2.29% -41.77%
Incyte Corp 75.50 0.99 1.32% -7.69%
Ionis Pharmaceuticals 37.47 0.87 2.36% 0.39%
Eli Lilly 301.15 1.77 0.59% 54.73%
MacroGenics 4.20 0.07 1.69% -86.35%
Merck & Co 93.00 0.68 0.74% 17.16%
Moderna Inc 142.18 5.92 4.34% -10.88%
Mirati Therapeutics 58.11 1.64 2.90% -62.63%
Neurocrine Biosciences 85.11 0.23 0.27% -8.57%
Nektar Therapeutics 3.91 0.03 0.64% -78.53%
Novartis 87.80 0.39 0.45% 10.14%
Puma Biotechnology 1.99 0.11 5.59% -80.65%
Pfizer 51.35 0.68 1.33% 28.20%
Ultragenyx Pharmaceutical 55.28 0.02 0.03% -49.88%
Seattle Genetics 144.58 2.04 1.43% -2.30%
Sanofi 52.64 0.08 0.15% -1.59%
Xencor 24.03 0.41 1.74% -39.47%

Indexes Price Day Year
USND 11985 321.73 2.76% -9.92%
US2000 1840 56.87 3.19% -16.76%
US400 2489 71.68 2.96% -7.47%

Exelixis
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options. The Company's cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. The products derived from cabozantinib are CABOMETYX tablets for renal cell carcinoma (RCC) and COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). Its other two product candidates are COTELLIC (cobimetinib), is an inhibitor of MEK with multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO (esaxerenone), is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) for the treatment of hypertension. Its phase I b clinical trial programs include XL092, STELLAR-001 and STELLAR-002.